Ravi Salgia

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.

A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration.

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.

Gemcitabine-induced radiation recall.

CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance.

Flow cytometric determination of lipid peroxidation using fluoresceinated phosphoethanolamine.

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.

Molecular alterations in lung cancer. Impact on prognosis.

Detection and analysis of lung cancer cells from body fluids using a rare event imaging system.

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.

Role of receptor tyrosine kinases in lung cancer.

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.

Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.

Molecular and cellular biology of small cell lung cancer.

2-methoxyestradiol alters cell motility, migration, and adhesion.

Circulating tumor cells and serum tumor biomarkers in small cell lung cancer.

Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases.

Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung.

Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate.

c-Met: structure, functions and potential for therapeutic inhibition.

Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors.

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

p53 and Bcl-2 in small cell-lung cancer.

Phase II study of imatinib in patients with small cell lung cancer.

Small cell lung cancer: from molecular biology to novel therapeutics.

Targeted molecules in small cell lung cancer.

Targeting c-Kit mutations: basic science to novel therapies.

Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system.

Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.

Therapeutic targeting of the receptor tyrosine kinase Met.

Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1.

Receptor tyrosine kinases and inhibitors in lung cancer.

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.

The role of ephrins and Eph receptors in cancer.

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.

Novel therapies in lung cancer.

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Therapeutic targeting of receptor tyrosine kinases in lung cancer.

Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.

Molecular biology of malignant mesothelioma: a review.

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.

Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.

Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.

c-Met inhibition.

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.

A review of topoisomerase inhibition in lung cancer.

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Lung carcinoma in African Americans.

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.

Tyrosine kinase mutations in human cancer.

Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.

Key signaling pathways and targets in lung cancer therapy.

c-Met is a potentially new therapeutic target for treatment of human melanoma.

Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.

Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.

Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.

CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.

Non-receptor tyrosine kinase inhibitors in lung cancer.

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Review of clinic trials: agents targeting c-Met.

Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue.

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.

MET as a target for treatment of chest tumors.

Expression and mutational analysis of MET in human solid cancers.

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Protein kinase C beta in malignant pleural mesothelioma.

EGFR-targeted therapeutics: focus on SCCHN and NSCLC.

FYN is overexpressed in human prostate cancer.

Stamp out lung cancer.

Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

MET pathway as a therapeutic target.

Role of c-Met in cancer: emphasis on lung cancer.

PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.

Ethnic differences and functional analysis of MET mutations in lung cancer.

Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.

Novel targets for therapeutic agents in small cell lung cancer.

Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.

MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.

MET receptor tyrosine kinase.

The role of EGFR inhibition in the treatment of non-small cell lung cancer.

MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.

PAX3 and SOX10 activate MET receptor expression in melanoma.

CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

MET molecular mechanisms and therapies in lung cancer.

The role of chemokine receptor CXCR4 in lung cancer.

Fyn: a novel molecular target in cancer.

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

The MET axis as a therapeutic target.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER.

Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.

Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.

Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.

Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.

Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.

Personalized treatment of lung cancer.

Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.

Crizotinib (PF02341066)、 双间充质上皮过渡 (MET) 和间变性淋巴瘤激酶 （ALK） 抑制剂，在 de novo MET 扩增与非小细胞肺癌病人的活动。

Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways.

Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.

Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).

Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-Small-Cell Lung Cancer, A Phase II Trial.

Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

MET and phosphorylated MET as potential biomarkers in lung cancer.

Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer.

Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer.